RENO, NV- February 24, 2014 - PPJ Enterprise (OTC Pink: PPJE) (http://www.ppjenterprise.com/), a proprietary automated health care software company, announced today that it has received a $10,000,000 plus funding offer to be used in executing its business plan.
The immediate funding is for up to $50,000 of convertible debt which will be used to finance company development and of this $30,000 has already been received. The funding commitment calls for $35,000 in funding every 10 business days, the lender also agrees to pay all legal, accounting, audit and OTCQB listing fees. Up to an additional $440,000 of funding will be provided for marketing and company development once certain milestones are attained. This includes a unique milestone which triggers when PPJE's stock price improves to .01 and other milestones when each phase in the S1 filing process is achieved. When the SEC registration becomes effective, an additional $10,000,000 in funding has been offered.
Ms. Chandana Basu, PPJE CEO, stated, "This is very exhilarating, as we achieve each of the necessary milestones along the SEC filing process, we will enjoy more than enough funding for a complete roll out of our automated billing software. Soon we also expect to begin operating our new Blood culture testing labs divisions."
About PPJ Enterprise
PPJ Enterprise is a proprietary automated health care practice management software company. We guarantee our customers a 30% increase in collections. Some physicians already using the software have reported a 50% increase in revenues and a 70% decrease in operating costs. PPJ Enterprise has 23 years of experience as a provider of full-service medical billing services. We excel in providing traditional, customized medical billing services and support to physicians, providers, and healthcare facilities across the nation. In addition to our core medical billing services, PPJ offers a comprehensive, full-service medical billing software product, The Automated Biller. We believe that ours is the only fully automated product poised to take over the huge health care billing market.
PPJ Enterprise is also in process of setting up a laboratory to perform Film Array Blood Culture Identification (BCID) Panel tests for a comprehensive list of 24 pathogens and 3 antibiotic resistance genes associated with bloodstream infections. One test identifies pathogens in 9 out of 10 positive blood cultures in about an hour with only two minutes of hands-on time.
Information in this news release may contain statements about future expectations, plans, prospects or performance of PPJ Enterprise, that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. PPJ Enterprise cautions you that any forward-looking information provided by or on behalf of PPJ Enterprise is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. PPJ Enterprise's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond PPJ Enterprise's control. In addition to those discussed in PPJ Enterprise's press releases, public filings, and statements by PPJ Enterprise's management, including, but not limited to, PPJ Enterprise's estimate of the sufficiency of its existing capital resources, PPJ Enterprise's ability to raise additional capital to fund future operations, PPJ Enterprise's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match PPJ Enterprise's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. PPJ Enterprise does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Investor Relations Department
1105 Terminal Way, Suite 202
Reno, Nevada 89502
Telephone: (775) 348-5735
Fax: (866) 622-3215
SOURCE: PPJ Enterprise